Pancreatic Cancer

Product Candidate / Program Drug substance Indication Discovery Pre-clinical Phase I Phase II Phase III / Pivotal EMA/FDA REVIEW
eryaspase Asparaginase Pancreatic Cancer EU then EU/US

Pancreatic cancer is a particularly aggressive cancer, with a five-year survival rate of less than 10%. We believe pancreatic cancer is a suitable indication for eryaspase because it involves a large proportion of tumors that are believed to be sensitive to L-asparaginase depletion, allowing our product candidate to potentially have an impact.

A phase 2b study showed positive results on 140 patients suffering from metastatic pancreatic cancer in second line.